KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBIT: 2012-2024

Historic EBIT for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$279.3 million.

  • Xenon Pharmaceuticals' EBIT fell 30.76% to -$96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$340.8 million, marking a year-over-year decrease of 33.37%. This contributed to the annual value of -$279.3 million for FY2024, which is 30.48% down from last year.
  • According to the latest figures from FY2024, Xenon Pharmaceuticals' EBIT is -$279.3 million, which was down 30.48% from -$214.1 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year EBIT high stood at -$31.3 million for FY2020, and its period low was -$279.3 million during FY2024.
  • In the last 3 years, Xenon Pharmaceuticals' EBIT had a median value of -$214.1 million in 2023 and averaged -$207.5 million.
  • Its EBIT has fluctuated over the past 5 years, first increased by 26.90% in 2020, then tumbled by 152.37% in 2021.
  • Xenon Pharmaceuticals' EBIT (Yearly) stood at -$31.3 million in 2020, then crashed by 152.37% to -$79.0 million in 2021, then slumped by 63.49% to -$129.1 million in 2022, then slumped by 65.75% to -$214.1 million in 2023, then slumped by 30.48% to -$279.3 million in 2024.